USPTOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die US-Marke GIGANUCLEASE wurde als Wortmarke am 16.01.2002 beim Amerikanischen Patent- und Markenamt angemeldet.
Sie wurde am 30.08.2005 im Markenregister eingetragen.
Der aktuelle Status der Marke ist "CANCELLED - SECTION 8".
| Markenform | Wortmarke |
| Aktenzeichen | 76359549 |
| Registernummer | 2988451 |
| Anmeldedatum | 16. Januar 2002 |
| Veröffentlichungsdatum | 07. Juni 2005 |
| Eintragungsdatum | 30. August 2005 |
Markeninhaber
28, rue du Dr Roux
75724 Paris Cedex 15
FR
75724 Paris Cedex 15
FR
Markenvertreter
Waren und Dienstleistungen
1
Chemicals, biochemical, biotechnological and bacteriological products namely, polypeptides for in vivo and invitro genetic engineering, natural and engineered meganuclease and endonuclease, nucleic acid vectors encoding the natural or engineered meganuclease or endonuclease or nucleic acid vectors comprising their recognition and cleavage site; ready to use genomic recombination system comprised primarily of reagents for scientific use; cells engineered by meganuclease recombination systems for scientific research use and therapeutic use, chemical agents, biochemical, biotechnologic and bacteriological products for use in scientific research laboratories and control laboratories namely cells, reagents, and culture media; diagnostic reagents for scientific use; proteins for use in scientific research; biotechnological preparations used as molecular scissors in scientific research
5
Pharmaceutical, veterinary, and health care products, namely polypeptides for in vivo and in vitro genetic engineering for use in the treatment of cystic fibrosis, Duchesne muscular dystrophy, and Alpha 1 antitrypsin disease; natural and engineered meganucleases and endonucleases, nucleic acid vectors encoding the natural or engineered meganuclease or endonuclease or nucleic acid vectors comprising their recognition and cleavage site, all for use in the treatment of sickle cell anemia, X-SciD, and Rs-SciD; ready to use genomic recombination system comprised primarily of meganuclease recombination system for use in the treatment of muscular dystrophy; cells engineered by meganuclease recombination system for use in the treatment of genetic and viral disease, microorganism cultures and bacteriological preparations for use in the treatment of genetic and viral disease; chemotherapeutic preparations for use in the treatment of cancer; diagnostic preparations for clinical medical use
42
Scientific and industrial research; research for others in genetic, medical, pharmaceutical, and veterinary fields; research for others in chemistry, biology, biochemistry, molecular biology, bacteriology; scientific analysis services, research and development for others of techniques of biochemical analysis, biological analysis, molecular biology techniques, research and development of new molecules intended for industry, scientific laboratory services; conducting scientific research studies relating to engineering, natural, and engineered meganuclease and endonuclease, and meganuclease recombination systems; licensing of patents and of intellectual property; computer programming for others; and development for others of software programs and multimedia products
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
ID: 1376359549